trial

Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography

NCTId NCT00942981

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

Phase — · Completed

Enrollment 283 (actual)

Sponsored by National Institute of Mental Health (NIMH)

Synthesized from structured facts only — each point cited above.

Design & status

Phase

—

Status

Completed

Enrollment

283 (actual)

Study type

Observational

Allocation

—

Model

—

Masking

—

Start

2009-11-13

Primary completion

—

Eligibility

ALL · 18 Years · 90 Years

Interventions & indications

Drugs

PET

Indications

Schizophrenia Schizoaffective Disorder Schizophrenia Psychotic Disorders

Investigators

Karen F Berman, M.D.Principal Investigator

Sites

1 total

Bethesda, United States

Facts & assertions

3 sourced

Enrollment

283

Phase

Status

COMPLETED

relationships

The graph out of here

drug

PET

drug

lead_sponsor

National Institute of Mental Health (NIMH)

company

indication

Schizophrenia

indication

Schizoaffective Disorder

indication

Schizophrenia

indication

investigator

Karen F Berman, M.D.

person